Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy U Lin

Showing results (261-270 of 330) with videos related to

Pageof 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
NPJ Breast Cancer|January 3, 2024
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancerJennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, et al.
JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2020
Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast CancerRomualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2018
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerDaniel G Stover, Heather A Parsons, Gavin Ha, et al.
Neuro-Oncology|June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsAyal A Aizer, Nayan Lamba, Manmeet S Ahluwalia, et al.
Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.
Nature Biomedical Engineering|April 6, 2019
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithiumGiorgio Seano, Hadi T Nia, Kyrre E Emblem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Pageof 33

Showing results (261-270 of 330) with videos related to

Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
NPJ Breast Cancer|January 3, 2024
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancerJennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, et al.
JAMA Oncology|December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical TrialIrene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2020
Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast CancerRomualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2018
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerDaniel G Stover, Heather A Parsons, Gavin Ha, et al.
Neuro-Oncology|June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsAyal A Aizer, Nayan Lamba, Manmeet S Ahluwalia, et al.
Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.
Nature Biomedical Engineering|April 6, 2019
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithiumGiorgio Seano, Hadi T Nia, Kyrre E Emblem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing ProgramBrittany L Bychkovsky, Tianyu Li, Jilliane Sotelo, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Pageof 33